advanced solid tumors
Conditions
Interventions
Drug: GSK6097608
GSK6097608 will be administered as an IV infusion
Drug: Dostarlimab
Dostarlimab will be administered as an IV infusion
Drug: GSK4428859A
GSK4428859A will be administered as an IV in
Sponsors
Ishibashi Hideyasu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Adults 20 years of age or older; -Female participants of childbearing potential must agree to use a highly effective form of contraception; -Histological or cytological documentation of locally advanced, recurrent, or metastatic solid malignancy; -Disease that has progressed after standard therapy for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate, or if no further standard therapy exists; -Measurable disease per RECIST 1.1 -Eastern cooperative oncology group (ECOG) performance status (PS) 0 to 1 -Life expectancy of at least 12 weeks. -Adequate organ function as determined by laboratory assessments. -Adequate cardiac ejection fraction as measured by echocardiogram. -Arm A, D, E ,F and G -Japan only: lives in Japan and is racially Japanese, defined as all biological grandparents being Japanese. -Arm D, E, F and G only: has been deemed suitable for assigned treatment based on assessment by the investigator.
Exclusion criteria
Exclusion criteria: Prior anti-cancer treatment including investigational agents, immune checkpoint inhibitors, chemotherapy, targeted therapy, and biological therapy: within 4 weeks or 5 half-lives of the drug, whichever is shorter. -Prior allogenic or autologous bone marrow transplantation or other solid organ transplantation. -Toxicity from previous anticancer treatment, including; greater than or equal to Grade 3 immune-mediated toxicity considered related to prior immunotherapy and that led to treatment discontinuation; or toxicity related to prior treatment that has not resolved. -Known additional malignancy that progressed or required active treatment within the last 2 years. -Uncontrolled or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis. -Active autoimmune disease that has required systemic disease-modifying or immunosuppressive treatment within the last 2 years. -Concurrent medical condition requiring the use of systemic immunosuppressive treatment. -Cirrhosis or current unstable liver or biliary disease per investigator assessment. -Active infection requiring systemic treatment, known human immunodeficiency virus infection, or positive test for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) -Prolonged QT corrected for heart rate according to Fridericia's formula as measured by electrocardiogram. -History of hypersensitivity to monoclonal antibodies. For combination therapy, history of hypersensitivity to dostarlimab or its excipients. -History or evidence of significant cardiovascular (CV) risk. -Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural effusions. -History of idiopathic pulmonary fibrosis; interstitial lung disease; organizing pneumonia; noninfectious pneumonitis that required steroids, or evidence of active, noninfectious pneumonitis. -Pregnant or lactating woman. -Receipt of live vaccine within 30 days of the start of study intervention. -Receipt of transfusion of blood products or administration of colony-stimulating factors within 14 days before the first dose of study intervention. -Major surgery less than 4 weeks before the first dose of study intervention. -Known drug or alcohol abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Number of participants with dose-limiting toxicities (DLTs) [ Time Frame: Up to Day 21 ] Number of participants with DLTs will be determined. 2.Number of participants with adverse events (AEs) [ Time Frame: Up to 2 years ] Number of participants with AEs will be assessed. 3.Number of participants with serious adverse events (SAEs) [ Time Frame: Up to 2 years ] Number of participants with SAEs will be assessed. | — |
Countries
canada, Japan, korea,republic of, united states
Contacts
Public ContactHideyasu Ishibashi
GlaxoSmithKline K.K.
Outcome results
None listed